Evidence map›Paper›PMID 21244649›Full record

ArticleJournal of immune based therapies and vaccines2011

Prior exposure to an attenuated Listeria vaccine does not reduce immunogenicity: pre-clinical assessment of the efficacy of a Listeria vaccine in the induction of immune responses against HIV.

James B Whitney, Saied Mirshahidi, So-Yon Lim, Lauren Goins, Chris C Ibegbu, Daniel C Anderson, Richard B Raybourne, Fred R Frankel, Judy Lieberman, Ruth M Ruprecht

Open access · hybridAbstract read
In one paragraph

Article in Journal of immune based therapies and vaccines, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. mBio · 2022
    Article
  3. Innate and Adaptive Immune Responses duringMicrobiology spectrum · 2019
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

James B WhitneyDivision of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA. jwhitne2@bidmc.harvard.edu.
Saied Mirshahidi
So-Yon Lim
Lauren Goins
Chris C Ibegbu
Daniel C Anderson
Richard B Raybourne
Fred R Frankel
Judy Lieberman
Ruth M Ruprecht
Harvard University · USDana-Farber Cancer Institute · USEmory University · USCenter for Food Safety and Applied Nutrition · USLoma Linda University · USUniversity of Pennsylvania · US

Funding

Mechanisms of SIV persistenceR56AI091514 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WHITNEY, JAMES BURTON · 2011 to 2011
$849k
NIAID NIH HHS R56 AI091514
6 · The paper itself

Abstract

backgroundWe have evaluated an attenuated Listeria monocytogenes (Lm) candidate vaccine vector in nonhuman primates using a delivery regimen relying solely on oral vaccination. We sought to determine the impact of prior Lm vector exposure on the development of new immune responses against HIV antigens.

findingsTwo groups of rhesus macaques one Lm naive, the other having documented prior Lm vector exposures, were evaluated in response to oral inoculations of the same vector expressing recombinant HIV-1 Gag protein. The efficacy of the Lm vector was determined by ELISA to assess the generation of anti-Listerial antibodies; cellular responses were measured by HIV-Gag specific ELISpot assay. Our results show that prior Lm exposures did not diminish the generation of de novo cellular responses against HIV, as compared to Listeria-naïve monkeys. Moreover, empty vector exposures did not elicit potent antibody responses, consistent with the intracellular nature of Lm.

conclusionsThe present study demonstrates in a pre-clinical vaccine model, that prior oral immunization with an empty Lm vector does not diminish immunogenicity to Lm-expressed HIV genes. This work underscores the need for the continued development of attenuated Lm as an orally deliverable vaccine.

Identifiers

PMID21244649
PMCPMC3033796
OpenAlexW2119978378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.